Gilead has $21.3 billion in cash on its balance sheet (equivalent to almost 20% of its market cap). With all of that firepower, Gilead can do a great deal to build out its pipeline or just buy its way into a new disease area. Consider, for example, its 2011 purchase of Pharmasset for $11 billion, which yielded Sovaldi and launched its Hepatitis C dominance.